GlaxoSmithKline has withdrawn the US application for its restless legs syndrome treatment Solzira. The company, along with co-developer XenoPort, is …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

